AI in Healthcare

The latest on artificial intelligence transforming medicine

News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.

Filtered by: AI drug developmentClear filter
opinionMSN

AI Drug Discovery Is Facing a Harder Question Than Hype: Does It Actually Work?

A wave of enthusiasm has lifted AI drug discovery into major fundraising and partnership deals, but skepticism is growing over whether the field can produce consistent clinical results. The central issue is no longer whether AI can help scientists think faster; it is whether it can reliably improve drug development outcomes.

AI drug developmenthype cycledrug discoveryvalidation
opinion

Can AI Drug Development Live Up to the Hype?

This broad look at AI drug development asks whether the field’s most ambitious claims can translate into real-world therapeutics. It arrives as investment and partnership activity are accelerating, making the question of evidence more urgent than ever.

MSN
AI drug developmentbiopharmahype
opinion

Why AI Drug Development Still Fails: The Industry Is Learning That Better Tools Need Better Questions

A new BioPharm International analysis argues that AI often falls short in drug development because teams use it on poorly framed problems. The piece is a useful corrective to the hype cycle, emphasizing that value comes from integrating AI into disciplined scientific and operational workflows.

BioPharm International
AI drug developmentbiotech workflowdrug discovery
industry

Senhwa Biosciences Secures Up to NT$500 Million to Push AI-Driven Drug Development

Senhwa Biosciences has secured strategic backing from GEM, giving the company fresh capital to accelerate AI-driven drug development. The funding highlights how investors still see AI-enabled biotech as a promising route, even as the sector faces tougher demands for proof and execution.

PR Newswire
Senhwa BiosciencesGEMfinancing
opinion

Insilico’s CEO Makes the Case for AI as a Drug-Development Workflow, Not a Magic Box

In comments to STAT, Insilico Medicine’s leadership framed AI’s best use in drug development as a practical system for narrowing uncertainty, not replacing scientific judgment. That framing reflects a broader maturation in the sector as companies shift from grand claims to integrated, stage-specific deployment.

statnews.com
Insilico MedicineSTATAI drug development

How this works

Discover

An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.

Structure

The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.

Publish

Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.